New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma News-Medical.net About 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a combination of rituximab, a drug that targets the protein CD20 found on B cells, and ... |
